TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Efficacy of Systemic Corticosteroids in AECOPD Patients With Higher Blood Eosinophil Levels

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Within 24 hours of admission;~2. Aged between of 40 and 80 years old;~3. Established clinical history of COPD with spirometry-verified COPD (defined as post-bronchodilator forced expiratory volume in one second (FEV1)/ forced vital capacity (FVC) ≤ 0.70);~4. AECOPD diagnosis in accordance with the GOLD guideline (An acute worsening of respiratory symptoms that result in additional therapy)12;~5. Current or former cigarette smokers (≥10 packs per year);~6. Blood eosinophil count \> 2% or \>300 cells/μL tested within 24 hours of admission;~7. Signed informed consent.~Exclusion Criteria:~1. Admission due to other diseases (pneumonia, pneumothorax, pulmonary interstitial disease, active tuberculosis or bronchiectasis, ect);~2. Regular use of glucocorticoid ≥3 months;~3. Received prednisone ≥ 60 mg in the past three days (or equivalent doses of other corticosteroid);~4. Allergic or intolerant to corticosteroid;~5. Participating in or completed another drug trial within 90 days;~6. Pregnancy or lactation;~7. Severe COPD exacerbation requiring invasive mechanical ventilation (IMV) or transfer to ICU within 24 hours after emergency admission or hospitalization;~8. With complications that may cause eosinophilia;~9. Pulmonary embolism within the past two years;~10. Myocardial infarction, uncontrollable congestive heart failure or arrhythmia within the past four weeks;~11. Comorbidity that may influence the immune system;~12. Malignant tumor;~13. Neuromuscular disease affecting the respiratory system;~14. Systemic fungal infection;~15. Thoracotomy or bronchoscopic lung volume reduction surgery history;~16. Adrenocortical insufficiency history;~17. Diabetes mellitus with poor glycemic control;~18. Uncontrollable severe psychiatric illnesses even with medication, cognitive impairment, and severe language difficulties;~19. ALT ≥ 100U/L or AST ≥ 80U/L;~20. Serum creatinine ≥ 162umol/L;~21. Life expectancy of less than 30 days.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Systemic corticosteroid group (Type: EXPERIMENTAL): Patients will receive Oral prednisone 40mg/day for five consecutive days in addition to standard treatment during emergency admission or hospitalization.
- Control group (Type: PLACEBO_COMPARATOR): Participating patients will receive an oral placebo of 40mg/day for five consecutive days in addition to standard treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of classic Hodgkin's lymphoma~* Must have completed first-line therapy without evidence of disease progression~PATIENT CHARACTERISTICS:~* HIV negative~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No more than 6 months since prior chemotherapy or radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Cell vaccine after initial therapy for Hodgkin lymphoma (Type: EXPERIMENTAL): Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Glycemic Control and Surgical Site Infection Incidence Among Liver Transplantation Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recipients of LT whose allograft came from deceased donors~* Able to give informed consent personally or via a family member who has appropriate authorization to do so if patient unconscious.~* Blood glucose level over 130 mg/dL in the first 24 hours postoperatively~Exclusion Criteria:~* The patients that underwent any kind of surgery with or without prosthesis implant in the 30 days before the LT~* Recipients submitted to multiple organ transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Strict Glycemic Control Group (Type: ACTIVE_COMPARATOR): Intravenous insulin as described by Keegan and Cols. 2010.
- Standard Glycemic Control Group (Type: ACTIVE_COMPARATOR): Subcutaneous insulin as instititional protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: a BavaRiAn eValuatiOn of Dorsal Root Ganglion (DRG) Stimulation for the Treatment for Chronic Post Surgical Pain of the Groin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. The patient is at least 18 years old~2. The patient is willing and able to comply with the examination schedule and the trial schedule.~3. The patient has suffered from chronic post-surgical neuropathic groin pain for at least 6 months~4. Conservative treatments of the chronic pain including medication, physiotherapy and interventions have been exhausted~5. The pain level at the time of the baseline examination is at least 60mm on the visual analogue scale (VAS) in the primary pain area (groin pain)~6. The patient is able to give consent in writing~Exclusion Criteria:~1. Pregnant or breastfeeding patients or those who plan to become pregnant during the study~2. It has been established in an examination by the tester that the pain has significantly worsened or changed its characteristics in the course of the previous month.~3. In the last 30 days, the patient has been treated with corticosteroids on an area scheduled for the stimulation.~4. In the last 3 months, the patient has been treated with radio frequency therapy on an area scheduled for the stimulation.~5. The patient has already been treated with an active implantable device, including an implantable cardioverter defibrillator, pacemaker, spinal cord stimulator or an intrathecal medication pump.~6. The patient is not able to operate the stimulation device~7. The patient is currently suffering from an infection~8. The patient has participated in another clinical study in the last 30 days~9. The patient has a coagulation disorder or is taking anti-coagulants, which would make participation impossible, as per the study doctor~10. The patient has been diagnosed with a malignancy in the past 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treated subjects (Type: None): All subjects recruited and treated with the Axium neurostimulator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Real-time Glaucoma Medication Adherence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and older~* Glaucoma diagnosis~* Prescription for a prostaglandin indicated for glaucoma~* Nonadherent (MPR\<80%) in the last 3 months according to pharmacy records~* Owns and operates a mobile phone and willing to receive periodic reminder messages~Exclusion Criteria:~* Existing chronic eye condition in addition to glaucoma~* Scheduled for eye surgery in the next 90 days~* Prescription for a medication that will not fit in the device~* Non-English speaking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Monitoring only (Type: ACTIVE_COMPARATOR): Patients in this arm will be given a real-time medication use monitor to use in dispensing their topical glaucoma medication for 3 months
- Monitoring and reminder (Type: EXPERIMENTAL): Patients in this arm will be given a real-time medication use monitor to use in dispensing their topical glaucoma medication for 3 months and will receive an automated reminder (text or voice) when a missed dose is determined by the device's system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Opioid Consumption in Cystectomy Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients undergoing cystectomy~* Capable and willing to consent~* Participants literate in English language~Exclusion Criteria:~* History of drug and/or alcohol abuse/dependency~* Ketamine use during hospitalization~* Illiteracy~* Presence of a clinically diagnosed major psychiatric condition such as bipolar disorder, uncontrolled major depression, schizophrenia~* Any condition that the principle investigator may disqualify the patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All Patients (Type: None): All cystectomy patients who consent for the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Combined Nutritional Therapies for the Treatment of Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients (from 18 to 65 years old) diagnosed with ulcerative colitis (not distal), of at least 1 year of evolution of the disease.~2. Patient in clinical remission two months prior to inclusion (Simple Colitis Clinical Activity Index (SCCAI) \<4) and fecal calprotectin \<150 μg / g.~3. At least one outbreak in the last year that required systemic corticosteroids or escalating treatment (initiation of thiopurines, optimization of thiopurines, initiation of anti-TNF-alpha, intensification of anti-TNF-alpha, initiation of vedolizumab). At the time of entry into the study, the patient must carry with stable medication at least 2 months in the case of anti-TNF-alpha and mesalazine and 5 months in the case of thiopurine, and without treatment with corticosteroids~Exclusion Criteria:~* Patients with ulcerative proctitis only~* Patients who have received antibiotics the month prior to inclusion until completion~* Usual consumption of probiotics excluding fermented milk (yogurt, kefir ...).~* Supplementation with dietary fiber (without taking into account the one administered in the study).~* The smoking habit is allowed, although the beginning or abandonment of it from two months before the end of the study will have to be documented.~* Patients undergoing hypocaloric diets~* Patients with stenosis or intestinal surgery~* Patients with primary sclerosing cholangitis~* Patients under treatment with ursodeoxycholic acid~* Patients under treatment with ion exchange resins~* Patients under treatment with acenocoumarol (Sintrom)~* The taking of proton pump inhibitors (PPIs) is allowed but their consumption must be controlled, not allowing them to start or suspend their intake during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A: 1 dosis (Type: ACTIVE_COMPARATOR): 1 dosis (3E+09 cfu/day + 6 g of fiber/day)
- B: 2 dosis (Type: ACTIVE_COMPARATOR): 2 dosis (3E+09 cfu/day + 12 g of fiber/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 21-75~* Body Mass Index (BMI) \>19 kg/m\^2~* Subjects with biopsy/MRE proven NASH \[MRE liver fat ≥ 5%, with elevated liver enzymes ALT \<5x upper limit normal (ULN)\].~* Subjects with NAFLD and MRE shows F0 or greater fibrosis~* Subjects with history suggestive of NAFLD/NASH~* Total bilirubin must be \< 1.5 x ULN and INR must be \< 1.3 at baseline screening.~* TSH and CPK will be within normal limits (WNL) at screening.~* Subjects with type 2 diabetes who are on stable doses of medications (except pioglitazone) to control hyperglycemia and have baseline HbA1c of 10% or lower.~* Hemoglobin must be greater than or equal to 12.0 in males and 11.0 in females.~Exclusion Criteria:~* Medications that may affect glucose metabolism such as corticosteroids, opiates, barbiturates, and anticoagulants.~* Subjects with anemia, and symptoms suggestive of undiagnosed illness, overt hepatic disease, stroke, Alzheimer's disease, autoimmune hepatitis, alcoholism or increased alcohol consumption over the American Diabetes Association (ADA) guidelines.~* Any disorder that may potentially impact the outcome measures.~* Pregnant women and children.~* Subjects planning weight loss or in any weight loss program.~* Subjects taking TZD's, Atazanavir, Indinavir, Ketoconazole, Valproic acid, Silybum marianum and Valeriana officinalis.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Active drug AZ compound (Type: EXPERIMENTAL): AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Reducing Sedentary Behaviour in Comparison to Promoting Physical Activity on Chronic Non-specific Low Back Pain in a Sedentary Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* CNLBP, for at least 3days/week for at least 3 months since the first symptoms.~* Failed back surgery syndrome is allowed (ie, more than 3 years ago, anatomically successful operation without symptom disappearance)~* Desk job, sedentary lifestyle (i.e. sitting for more than 6 hours per day). Given the greater risk of developing serious health problems when sitting for more than six hours a day.~* 18-65 years old~* Native Dutch speaker~* Refraining from analgesics, caffeine, alcohol or nicotine in the previous 48h of the assessments~* Not undertaking exercise (\>3 metabolic equivalents) 3 days before the assessments~* Both sexes~* Experiencing chronic neck pain is allowed if CNLBP is the dominant complaint.~Exclusion Criteria:~* Any specific cause that can explain the CNLBP~* Physically demanding job (e.g. nurses, paramedics, construction workers,...)~* Chronic widespread pain (i.e. fibromyalgia, chronic fatigue syndrome)~* Chronic systematic diseases such as rheumatoid arthritis, diabetes, etc.~* Neuropathic pain~* Being pregnant or pregnancy (including giving birth) in the preceding year~* History of specific spinal surgery~* Cinical depression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: NO_INTERVENTION): This group will be asked to maintain their daily routine.
- Reducing sedentary behavior (Type: EXPERIMENTAL): This group needs to download an app on their computer and their smartphone. This app will give a notification every 30 minutes to walk during 2 minutes during working hours.
- Increase physical activity (Type: EXPERIMENTAL): This group will be asked to be more physically active. They need to be active during 150min/week. Additionnaly they need to be active in periods of at least 10 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male, must be ≥ 18 years of age, with histologically confirmed prostate adenocarcinoma, that is clinically localized to the prostate gland~* Stable sexual relationship for ≥ 6 months~* Open or laparoscopic bilateral nerve-sparing radical prostatectomy~* Baseline score of ≥ 22 on the International Index of Erectile Function Domain (Appendix A)~* Able to speak, read and write in the English language~* Calculated creatinine clearance using the 4 variable MDRD equation based on serum creatinine, age, race, and gender of \> 60 cc/min~* Patient is able to walk up two flights of stairs briskly without chest pain~* Patient needs to have their baseline sitting AND standing blood pressure and pulse done at the time of consent~Exclusion Criteria:~* Preoperative or planned postoperative pelvic radiation therapy~* Preoperative or planned postoperative androgen deprivation~* Presence of Peyronie's disease at baseline~* Presence of a penile prosthesis at baseline~* Resection of one or both nerve bundles at surgery~* Any contraindications to sildenafil:~  * Patient is currently using nitrates;~ * Presence of retinitis pigmentosa;~ * Presence macular degeneration;~ * MI or CVA within 3 months;~ * Patient is currently using MAOI medications~* Patient is currently using penile self injection medication (Trimix, Bimix, or PGE-1)~* Patient requiring sildenafil for penetration~* Use of sildenafil within 30 days of consent

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PRN Sildenafil (Type: EXPERIMENTAL): Placebo QHS (blinded) and sildenafil 100mgs (open-label) as required for sexual relations. The placebo will be omitted on nights that 100mgs is used. Placebo will start within 24-48 hours post-surgery.
- Nightly Sildenafil Arm (Type: EXPERIMENTAL): Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery.
- Combination Therapy Arm (Type: EXPERIMENTAL): Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL), at initial dose of 5 units (0.05ml) will be given; the first 2 injections will be done in the MSKCC urology outpatient clinic (if needed, the investigator can determine appropriate amount of injections for patient training).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults (age 18 to 65 years of age), male or female Hispanic or Caucasian.~2. Primary kidney or kidney transplant patients (cadaveric, living related, or living unrelated)~3. Written inform consent obtained. The patients are willing to participate in the study at UTMB.~4. Female with negative pregnancy test.~5. PRA \< 20 %.~6. En-blocks and two kidneys (tx'd at the same time) will be allowed.~7. Cold Ischemia time ≤ 30 hrs~8. Hep C patients will be allowed to enroll in this study~Exclusion Criteria:~1. Multi-organ transplants~2. Transplant from non-heart beating donor (NHBD) or dual transplants~3. A-B-O incompatible or positive cross match~4. Conditions which significantly alter the absorption, distribution, and metabolism (except for diarrhea) of medications.~5. Women of childbearing potential not using contraception method(s) as well as women who are breastfeeding~6. Inability to tolerate oral medications~7. Inability to sign a written consent form or to cooperate with investigators~8. Use of an investigational medication in the past 30 days.~9. Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (specify as required)~10. HIV positive patients~11. History of psychosocial instability~12. Mental incompetence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Transplant recipients (Type: EXPERIMENTAL): All subjects receive identical drug treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues